| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Clinical |
Department of Immunology, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania
Requests for reprints: Olivera J. Finn, E1040 Biomedical Science Tower, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261. Phone: 412-648-9816; Fax: 412-383-8859; E-mail: ojfinn{at}pitt.edu.
Purpose: Cyclin B1–derived peptides were shown by us to be targets of tumor-specific CD8+ T cells in patients with breast and head and neck cancer. We obtained further evidence of cyclin B1 immunogenicity and its potential to serve as a tumor-specific antigen by analyzing its ability to elicit T cell–dependent humoral immune responses in vivo in patients with different types of tumors.
Experimental Design: Recombinant cyclin B1 protein from two different sources was purified and used as antigen in ELISA assays to test sera from patients with breast, pancreatic, colon, and lung cancer for the presence of anti-cyclin B1 antibody. We also analyzed patients with benign lung disease, premalignant disease, and a known history of heavy smoking.
Results and Conclusions: Cyclin B1 elicits helper T cell–dependent antibody responses in vivo. Tumors with higher level of cyclin B1 expression elicit higher anti-cyclin B1 antibody levels. Antibodies in patients with breast and colon cancer are primarily of the IgG isotype whereas patients with pancreatic and lung cancer have in addition anti-cyclin B1 IgA. Cyclin B1–specific IgG was also detected in long-term smokers and in patients with preneoplastic lung disease. Immune responses to aberrantly expressed cyclin B1 in tumors and premalignant lesions should be further explored as diagnostic and prognostic markers, in addition to their immunotherapeutic potential.
Key Words: tumor antigen • cancer vaccine • cell cycle
This article has been cited by other articles:
|
|
 |
|
  E. Kondo, B. Maecker, M. R. Weihrauch, C. Wickenhauser, W. Zeng, L. M. Nadler, J. L. Schultze, and M. S. von Bergwelt-Baildon Cyclin D1-Specific Cytotoxic T Lymphocytes Are Present in the Repertoire of Cancer Patients: Implications for Cancer Immunotherapy Clin. Cancer Res., October 15, 2008; 14(20): 6574 - 6579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Finn Immunological Weapons Acquired Early in Life Win Battles with Cancer Late in Life J. Immunol., August 1, 2008; 181(3): 1589 - 1592. [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Finn Cancer Immunology N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Spisek, A. Kukreja, L.-C. Chen, P. Matthews, A. Mazumder, D. Vesole, S. Jagannath, H. A. Zebroski, A. J.G. Simpson, G. Ritter, et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy J. Exp. Med., April 16, 2007; 204(4): 831 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Egloff, L. A. Vella, and O. J. Finn Cyclin B1 and Other Cyclins as Tumor Antigens in Immunosurveillance and Immunotherapy of Cancer Cancer Res., January 1, 2006; 66(1): 6 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.M. Tan, J. A. Koziol, Y. Kida, M. A. Thorat, R. A. Badwe, B. Rocco, B. Djavan, O. de Cobelli, X. Wang, D. Ghosh, et al. Autoantibodies in prostate cancer. N. Engl. J. Med., December 29, 2005; 353(26): 2815 - 2817. [Full Text] [PDF]
|
|
|
|
|
|
O. J. Finn Immune Response as a Biomarker for Cancer Detection and a Lot More N. Engl. J. Med., September 22, 2005; 353(12): 1288 - 1290. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
